Bettina Ryll, a medical doctor and PhD working with the Melanoma Patient Network Europe, gave a presentation on clinical benefit from the patient's perspective. She declared potential conflicts of interest related to past and present funding and consulting work for pharmaceutical companies. Her key messages were that from a patient's perspective, clinical benefit means how a treatment impacts pain, function and normalcy, rather than just anatomical outcomes, and that capturing variability is important to understand full benefit. She thanked her audience and provided contact information.

1. Clinical benefit
from a patient’s perspective
Bettina Ryll, MD/PhD
Melanoma Patient Network Europe
Cancer Mission Board
ESMO faculty Investigational Immuno-oncology

2. Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
DECLARATION OF INTERESTS
Bettina Ryll
• MPNE (Melanoma Patient Network Europe) is a volunteer-based network whose activities are funded by
balanced support by the following companies: Amgen, BMS, Delcath, Idera, Incyte, Immunocore, MSD,
Merck Serono, Novartis, Pierre Fabre, Roche. Support never includes editorial rights, influence on MPNE’s
program nor activities. In addition, MPNE is funded by 3 Horizon2020 grants (UMCURE, Share4Rare and
iTobos).
• Unfortunately, we have been unsuccessful in diversifying our funding sources by support from
regulatory, HTA and payer bodies or medical societies.
• In the last 3 years, BR received personal consultancy fees for work in patient affairs from- Amgen,
AstraZeneca, BMS, Celgene, Clinigen, IQVIA, MSD, Novartis, Pfizer, Roche.
• BR’s work for MPNE outside the Horizon2020 projects is non-remunerated
• Since 2019, BR is member of the EU Cancer Mission Board
B. Ryll

3. Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
B. Ryll

4. Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
when you are the patient, what matters is
clinical benefit, the conclusion
• who defines what your benefit is supposed to be- you yourself or someone else
• anatomical location as determining impact- pain, loss of function
• context- how much normalcy can you maintain?
• how the benefit gets captured and analysed
• that missing variability means missing benefit
B. Ryll

5. European Society for Medical Oncology (ESMO)
Via Ginevra 4, CH-6900 Lugano
T. +41 (0)91 973 19 00
esmo@esmo.org
esmo.org
Thank you
bettina.ryll@mpneurope.org